Comparative Pharmacology
Head-to-head clinical analysis: INCRELEX versus KEPIVANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCRELEX versus KEPIVANCE.
INCRELEX vs KEPIVANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin-like growth factor 1 receptor agonist; promotes linear growth by stimulating chondrocyte proliferation at epiphyseal plates and exerts anabolic effects on muscle, bone, and other tissues.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.
Intravenous bolus of 0.1 mg/kg given over 1 minute, followed by continuous intravenous infusion of 0.6 mg/kg/min for 30 minutes. Alternatively, a single intravenous bolus dose of 0.3 mg/kg.
60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.
None Documented
None Documented
Terminal elimination half-life is approximately 8-10 hours in adults; clinically, steady-state is achieved within 2-3 days.
Terminal elimination half-life is approximately 4.5 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), half-life is prolonged up to 2-fold, requiring dose adjustment. The half-life supports once-daily dosing for 3 consecutive days before chemotherapy.
Renal: ~95% of absorbed dose as unchanged drug and metabolites; fecal: <5%.
Primarily renal; approximately 90% of the dose is excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Growth Factor
Growth Factor